• Principal Investigator, Doctoral Advisor
• Peking Cancer Hospital
  Institute of Medical Technology, Peking University Health Science Center
  Chairman, Key Laboratory of Radiopharmaceutical Research and Evaluation, National Medical Products Administration
  National Biomedical Imaging Center

• 个人简介

  The Department of Nuclear Medicine, Peking University Cancer Hospital is now the Key Laboratory of Radioactive Drug Research and Evaluation of the State Food and Drug Administration, the Center for Radiopharma Research and Development and Clinical Application of the China Atomic Energy Authority, and the Nuclear Medicine Professional Base of the National Drug Clinical Testing Institution. It is the supporting unit of Beijing Nuclear Medicine Quality Control and Improvement Center, the chairman-in-waiting unit of the Nuclear Medicine Branch of Beijing Medical Association, and the chairman unit of the Radiopharmaceutical Branch of Chinese Nuclear Society. With an area of 2000 square meters, it has 3 sets of PET/CT, 2 sets of SPECT(/CT), 1 set of PET/MR, 1 set of cyclotron, 1 set of PET/CT for small animals and 6 sets of synthesis modules.
  Laboratory research directions: 1. PET immunoimaging research; 2. 2. Study on multi-modal molecular image probe; 3. Research on new PET molecular image probe; 4. Clinical transformation of tumor targeting molecular probes; 5. Preparation of tumor targeting radiopharma and animal experiments; 6. Research on the application of molecular imaging in integrative Chinese and Western medicine.

• 所授课程

  Tumor Nuclear Medicine (elective, 1 credit)

• 获奖及荣誉

  1996, "Study on 99mTc directly labeled monoclonal antibody", First Prize in Science and Technology Progress, Beijing Municipal Health Bureau
  2008.12, "Clinical and Basic Research on the Comprehensive treatment of colorectal cancer", Third Prize, China Medical Science and Technology Award
  2009.12, "Clinical and Basic Research on Comprehensive Treatment of colorectal Cancer", third prize of Beijing Science and Technology Award
  2018.10, "Innovation and Application of axillary lymph node treatment pathway for primary breast Cancer", third prize of Chinese Medical Science and Technology Award
  2019.12, "Technology Innovation and Transformation application of Positron emission Tomography (PET) imaging", Second Prize of China Medical Science and Technology Award, 4th Accomplisher
  In 2019, "Development and clinical transformation of sentinel lymph node specific probe", the third prize of Beijing Medical Science and Technology Award

• 个人履历

  2014/06-present: Beijing Cancer Hospital, Nuclear Medicine Department, Researcher and Director
  June 1999-June 2014: Beijing Cancer Hospital, Nuclear Medicine Department, Associate Researcher, Deputy Director, Director
  June 1994-June 1999: Beijing Cancer Hospital, Nuclear Medicine Department, Assistant Researcher
  Dec. 1992 -- May 1994: Beijing Cancer Hospital, Nuclear Medicine Department, Research Intern
  1989/07-1992/12: Institute of Isotopes, China Institute of Atomic Energy, Research Intern
  2006/09-2009/06: China Institute of Atomic Energy, Radioisotope Application, Doctor of Engineering
  2005/10-2005/12, 2006/04-2007/11: Visiting Scholar, Department of Experimental Imaging in Oncology, MD Anderson, University of Texas, USA
  2000/09-2003/07: Peking University, Department of Technical Physics, Nuclear Technology Application, Master
  1985/09-1989/07: Sichuan University, Department of Chemistry, Radiochemistry, Bachelor of Science

• 团队成员

  ZHU Hua, Researcher
  LIU Teli, Assistant Researcher
  LIU Futao, Assistant Researcher
  MENG Xiangxi, Assistant Researcher
  WANG Feng, Senior Technologist
  FAN Xiang, Secretary

• 承担项目

  1. National Natural Science Foundation of China, Project number: Construction of CD25 targeting probe and its application in CAR-T therapy imaging, Approval number: 82171980 (202/1 --2025/12), Project Leader, 550,000 RMB
  2. National Natural Science Foundation of China, Preliminary project: Construction of A2δ1 positive specific PET probe for diagnosis and treatment of hepatoma stem cells, Approval number: 81871386 (2019/1 -- 2020/12), Project leader, 570,000 RMB
  3. National Natural Science Foundation of China, Project: Construction of 68Ga/ 177Lu-PA probe targeting somatostatin receptor subtypes and its application in individualized tumor diagnosis and treatment, Approval number: 81571705 (2016/1-2019/12), Project leader, 550,000 RMB
  4. National Natural Science Foundation of China, surface project: Construction of Cu-64 labeled dinitroimidazole anoxic molecular probe and its application in tumor response diagnosis and treatment, Approval number: 81371592 (2014/01-2017/12), Project Leader, 700,000 RMB
  5. National Natural Science Foundation of China, Project number: 81172082 (2012/01-2014/12), Project Leader, 600,000 RMB
  6. National Natural Science Foundation of China, Multifunctional molecular imaging of tumor targeting nanoprobe NIRF-CCPM-RGD, 81071198 (2011/01-2013/12), Project Leader, 320,000 RMB
  7. National Key Research and Development Program, Breast Special Low-dose Multi-functional CT technology Research, Approval number: 2016YFC0100402, (2016/7-2019/7), sub-project leader, 750,000 RMB
  8. Natural Science Foundation of Beijing, Key project: Amino acid metabolism imaging of tumor with 18F-fluoroglutamine probe and its mechanism related to Myc gene regulation, 7171002 (2017/1-2019/12), Project Manager, 800,000 RMB

• 代表性论文及论著

  1.Xin Zhou †, Jiang Jinquan†, Yang Xue†, Teli Liu, Jin Ding, Nimmagadda S, Pomper MG, Hua Zhu *, Jun Zhao *, Zhi Yang *, Nan Li *. First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET. J Nucl Med. 2022 Apr;63(4):536-542.
  2. Ziren Kong†, Zhu Li †, Junyi Chen †, Wenbin Ma, Yu Wang*, Zhi Yang*, Zhibo Liu*, Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors, EJNMMI Res, 2022, 12(1):22.
  3. Nina Zhou†, Chang Liu†, Xiaoyi Guo†, Yuping Xu, Jifang Gong, Changsong Qi, Xiaotian Zhang, Ming Yang*, Hua Zhu*, Lin Shen*, Zhi Yang*. 68Ga-NOTA-MAL- MZHER2 PET Imaging in advanced gastric cancer patients and therapeutic response monitoring. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48:161–175.
  4. Zhu Hua*†; Zhang Hanwen†; Zhou Nina†; Ding Jin; Jiang Jinquan; Liu Teli; Liu Ziyu; Wang Feng; Zhang Qian; Zhang Zhuochen; Yan Shi; Li Lei; Benabdallah Nadia; Jin Hongjun; Liu Zhaofei; Cai Lisheng; Thorek Daniel L. J*.; Yang Xing*; Yang Zhi*。 Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS-CoV-2. ADVANCED SCIENCE 2021, 8, 2100965.
  5. Wang Shujing†, Zhu Hua†, Li Yingjie†, Ding Jin, Wang Feng, Ding Lixin, Wang Xinyu, Zhao Jun, Zhang Yan, Yao Yunfeng, Zhou Tong, Li Nan*, Wu Aiwen*, Yang Zhi*. First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer. J Immunother Cancer. 2021 Jul;9(7):e002926.
  6. Wang Shuailiang, Zhou Xin, Xu Xiaoxia, Ding Jin, Liu Song, Hou Xingguo, Li Nan, Zhu Hua*, Yang Zhi*. Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4259-4271.
  7. Xiaoxia Xu†, Hua Zhu†, Fei Liu, Yan Zhang, Jianhua Yang, Lifang Zhang, Qing Xie, Lin Zhu, Nan Li*, Hank F. Kung*, Zhi Yang*. Dynamic PET/CT imaging of 18F-(2S, 4R)4-fluoroglutamine in healthy volunteers and oncological patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020 Sep;47(10):2280-2292.
  8. Xiaoyi Guo†, Nina Zhou†, Zuhua Chen†, Teli Liu, Xiaoxia Xu, Xia Lei, Lin Shen, Jing Gao, Zhi Yang*, Hua Zhu1,*. Construction of 124I-trastuzumab for Noninvasive PET Imaging of HER2 Expression: From Patient-derived Xenograft Models to Gastric Cancer Patients. Gastric Cancer. 2020：1-13.
  9. Chen Liu†, Teli Liu†, Zhongyi Zhang†, Ning Zhang, Peng Du, Yong Yang, Yiqiang Liu, Wei Yu, Nan Li, Michael A Gorin, Steven P. Rowe*, Hua Zhu*, Kun Yan*, Zhi Yang*. 68Ga-PSMA PET/CT and standard plus PET/CT-Ultrasound fusion targeted prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsies. Journal of Nuclear Medicine. 2020 Sep;61(9):1314-1319.
  10. Teli Liu†, Chen Liu†, Xiaoxia Xu, Fei Liu, Xiaoyi Guo, Nan Li, Xuejuan Wang, Jianhua Yang, Xing Yang, Hua Zhu*, Zhi Yang*. Preclinical evaluation and primary clinical study of Al18F-PSMA-BCH in PET imaging of prostate cancer. Journal of Nuclear Medicine, 2019, 60:1284-1292.